Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands.
BACKGROUND
Medication-related adverse events (MRAEs) form a large proportion of all adverse events in hospitalized patients and are associated with considerable preventable harm. Detailed information on harm related to drugs administered during hospitalization is scarce. Knowledge of the nature and preventability of MRAEs is needed to prioritize and improve medication-related patient safety.


OBJECTIVE
To provide information on the nature, consequences and preventability of MRAEs occurring during hospitalization in the Netherlands.


METHODS
Analysis of MRAEs identified in a retrospective chart review of patients hospitalized during 2004.


METHODS
The records of 7889 patients admitted to 21 hospitals in 2004 were reviewed by trained nurses and physicians using a three-stage process. For each hospital, patient records of 200 discharged and 200 deceased patients were randomly selected and reviewed. For each patient record, characteristics of the patient and the admission were collected. After identification of an MRAE the physician reviewers determined the type, severity, preventability, drug category and excess length of stay associated with the MRAE. Data on additional interventions or procedures related to MRAEs were obtained by linking our data to the national hospital registration database. The excess length of stay and the additional medical procedures were multiplied by unit costs to estimate the total excess direct medical costs associated with the MRAE.


RESULTS
In total, 148 MRAEs occurred in 140 hospital admissions. The incidence of MRAEs was 0.9% (95% CI 0.7, 1.2) and the incidence of preventable MRAEs was 0.2% (95% CI 0.1, 0.4) per hospital admission. The majority of non-preventable MRAEs were adverse drug reactions caused by cancer chemotherapy. Preventable MRAEs were most often found in relation to anticoagulant treatment administered in combination with NSAIDs. Both non-preventable and preventable MRAEs resulted in considerable excess length of hospital stay and costs. On average, MRAEs resulted in an excess length of stay of 6.2 days (95% CI 3.6, 8.8) and average additional costs of &U20AC;2507 (95% CI 1520, 3773).


CONCLUSIONS
This study was the first to provide detailed information on MRAEs during hospital admissions in the Netherlands, which were associated with both considerable patient harm and additional medical costs. To increase patient safety, interventions need to be developed that reduce the burden of MRAEs. These interventions should target the areas with the highest risk of MRAEs, notably antibacterials, cancer treatment, anticoagulant treatment and drug therapy in elderly patients.
Hoonhout
Lilian H F
LH
VU University Medical Centre, EMGO+ Institute, Department of Public and Occupational Health, Amsterdam, the Netherlands. lilian.hoonhout@vumc.nl
de Bruijne
Martine C
MC
Wagner
Cordula
C
Asscheman
Henk
H
van der Wal
Gerrit
G
van Tulder
Maurits W
MW
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data*; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D017721:Hospital Costs; D006761:Hospitals / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D004364:Pharmaceutical Preparations / Q000191:economics; D012189:Retrospective Studies; D012720:Severity of Illness Index; D055815:Young Adult
D004364:Pharmaceutical Preparations
Int J Qual Health Care. 2003 Dec;15 Suppl 1:i49-59
14660523
Arch Intern Med. 1995 Oct 9;155(18):1949-56
7575048
J Chronic Dis. 1987;40(5):373-83
3558716
BMC Health Serv Res. 2008 Oct 24;8:220
18950476
J Qual Clin Pract. 1999 Mar;19(1):7-12
10096717
Qual Saf Health Care. 2005 Oct;14(5):358-63
16195570
Patient Educ Couns. 2006 Sep;62(3):302-15
16879943
Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):365-71
18302300
Ann Pharmacother. 2000 Dec;34(12):1373-9
11144691
JAMA. 2003 Oct 8;290(14):1868-74
14532315
Drugs Aging. 2008;25(1):49-59
18184029
Drug Saf. 2002;25(2):135-43
11888354
Qual Saf Health Care. 2007 Aug;16(4):285-90
17693677
Arch Intern Med. 2008 Sep 22;168(17):1890-6
18809816
Med J Aust. 1995 Nov 6;163(9):458-71
7476634
J Natl Cancer Inst. 2007 Apr 18;99(8):592-600
17440160
Int J Cancer. 2009 Feb 1;124(3):722-8
18989899
N Engl J Med. 1991 Feb 7;324(6):370-6
1987460
Int J Med Inform. 2008 Jun;77(6):365-76
18023611
Med Care. 2000 Mar;38(3):261-71
10718351
JAMA. 1997 Jan 22-29;277(4):301-6
9002492
JAMA. 1995 Jul 5;274(1):29-34
7791255
J Clin Epidemiol. 2010 Jan;63(1):94-102
19473812
Qual Saf Health Care. 2009 Aug;18(4):297-302
19651935
BMJ. 2000 Mar 18;320(7237):788-91
10720369
Stat Med. 2000 Dec 15;19(23):3219-36
11113956
Arch Intern Med. 2004 Apr 12;164(7):785-92
15078649
BMC Health Serv Res. 2007 Feb 25;7:27
17319971
Jt Comm J Qual Patient Saf. 2008 Apr;34(4):196-200
18468356
CMAJ. 2004 May 25;170(11):1678-86
15159366
Ann Intern Med. 2006 Sep 19;145(6):426-34
16983130
Pharmacoeconomics. 2002;20(7):443-54
12093300
N Engl J Med. 1991 Feb 7;324(6):377-84
1824793
JAMA. 1998 Apr 15;279(15):1200-5
9555760
Pharmacoeconomics. 2003;21(4):263-71
12600221
Can J Anaesth. 2001 Feb;48(2):139-46
11220422
N Z Med J. 2002 Dec 13;115(1167):U271
12552260
Qual Saf Health Care. 2003 Jun;12(3):194-200
12792009
JAMA. 1997 Jan 22-29;277(4):307-11
9002493
Drug Saf. 2000 Feb;22(2):161-8
10672897
J Health Serv Res Policy. 2008 Apr;13(2):85-91
18416913
Qual Saf Health Care. 2008 Jun;17(3):216-23
18519629
Drug Saf. 2007;30(5):379-407
17472418